top of page

PAR2 Pepducins in Atopic Dermatitis

PAR2 Pepducin-Based Suppression of Inflammation

and Itch in Atopic Dermatitis Models

Barr T., Garzia C., Guha S., Fletcher E., et al. Journal of

Investigative Dermatology. February 2019. 

DOI: 10.1016/j.jid.2018.08.019

Targeting PAR2 with Pepducins

Mellisa S. Lee & Ethan A. Lerner. Journal of Investigative Dermatology. August 2018. 

DOI: 10.1016/j.jid.2018.09.008

Phase 1 and Phase 2 Clinical Trials with a PAR1 Pepducin

PAR2 Pepducins in NASH, Fibrosis & Inflammation

PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference

A M ShearerY WangE K FletcherR RanaE S MichaelN NM F AbdelmalekL CovicA Kuliopulos Hepatology Dec 2022.



Targeting Liver Fibrosis with a Cell Penetrating Protease-activated Receptor-2 (PAR2) Pepducin

Shearer A.M., Rana R., Austin, K., et al. J Biol Chem. October 2016. 

DOI: 10.1074/jbc.M116.732743

Interdicting protease-activated receptor 2-driven inflammation with cell-penetrating pepducins

Sevigny L.M., Zhang P., Bohm A., Lazarides K. et al.

Proc Natl Acad Sci USA. May 2011. 

DOI: 10.1073/pnas.1017091108

PAR2 Pepducins Suppress Pancreatitis

Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis

L Van Doren, Nguyen N, Garzia C, Fletcher EK, Stevenson R, Jaramillo D, Kuliopulos A, Covic L Arterioscler Thromb Vasc Biol. Jan 2021

Pepducin Review

Lipopeptide Pepducins as Therapeutic Agents

Michael, ECovic LKuliopulos AMethods Mol Biol.

2022 DOI: 10.1007/978-1-0716-1752-6_21.

GPR31 Anti-stroke/thrombotic Pepducin

Pepducins and Cancer

Protease-Activated Receptor 1 as a Therapeutic Target in Breast, Lung and Ovarian Cancer: Pepducin Approach

Covic L & Kuliopulos A. Int. J. Mol Sci. 

July 2018. DOI: 10.3390/ijms19082237

PAR1 Pepducin Therapy Targeting Myocardial Necrosis in CAD and ACS Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study

Kuliopulos, A., Gurbel P.A, Rade, J.J. et al.

Atheroscler Thromb Vasc Biol. December 2020

DOI: 10.1161/ATVBAHA.120.315168


Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects with Coronary Artery Disease

Gurbel P.A, Bliden K.P., Turner U.S., Gesheff M.G. et al.

Atheroscler Thromb Vasc Biol. January 2016

DOI: 10.1161/ATVBAHA.115.306777

Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute biliary pancreatitis

Michael ES, Kuliopulos A, Covic L, et al. Am J Physiol Gastrointest Liver Physiol. Mar 2013. 

DOI: 10.1152/ajpgi.00296.2012

bottom of page